Bausch Health Canada, a subsidiary of Bausch Health Companies, has listed the 75mg and 100mg dosages of PrOKEDI in the Régie de l'assurance maladie du Québec formulary. PrOKEDI is an injectable risperidone suspension for adults with schizophrenia that achieves therapeutic levels within hours without oral supplementation and provides sustained release over four weeks. The company called the listing a major milestone toward reimbursement in Quebec and said it will continue pursuing coverage in other provinces. This follows a June 9 announcement that Bausch Health Canada completed negotiations with the pan-Canadian Pharmaceutical Alliance, resulting in a Letter of Intent for both dosages.
Bausch Health Companies IncPrOKEDI dosages listed in Quebec's RAMQ formulary, a regulatory milestone enabling reimbursement.